RATIONALE: Several studies suggest that repeated nicotine administration causes alterations in glutaminergic transmission that may play an important role in developing and maintaining nicotine addiction. Chronic nicotine administration in rats decreases the expression of the glutamate transporter-1 (GLT-1) and cysteine-glutamate exchanger (system xC-) in the nucleus accumbens. We hypothesized that ceftriaxone, a GLT-1 and system xC- activator, would decrease murine behavioral aspects of nicotine dependence. OBJECTIVE: This study aimed to investigate the effect of repeated ceftriaxone administration on the behavioral effects of nicotine using mouse models of conditioned reward and withdrawal. METHOD: Using male ICR mice, the ability of repeated ceftriaxone injections to modulate the development and reinstatement of a nicotine-conditioned place preference (CPP) was evaluated. Additionally, nicotine withdrawal-associated signs were assessed. These included both physical (somatic signs and hyperalgesia) and affective (anxiety-related behaviors) withdrawal signs in mice. Finally, the effects of ceftriaxone on nicotine-induced antinociception and hypothermia after acute nicotine injection were measured. RESULT: Ceftriaxone had no effect on the development of nicotine preference but significantly attenuated nicotine-induced reinstatement of CPP. Furthermore, ceftriaxone reversed all nicotine withdrawal signs measured in mice. CONCLUSION: Altogether, these findings show that a β-lactam antibiotic reduces nicotine withdrawal and nicotine-seeking behavior. Our results suggest that the documented efficacy of ceftriaxone against cocaine and morphine dependence-related behaviors effects extends to nicotine.
RATIONALE: Several studies suggest that repeated nicotine administration causes alterations in glutaminergic transmission that may play an important role in developing and maintaining nicotine addiction. Chronic nicotine administration in rats decreases the expression of the glutamate transporter-1 (GLT-1) and cysteine-glutamate exchanger (system xC-) in the nucleus accumbens. We hypothesized that ceftriaxone, a GLT-1 and system xC- activator, would decrease murine behavioral aspects of nicotine dependence. OBJECTIVE: This study aimed to investigate the effect of repeated ceftriaxone administration on the behavioral effects of nicotine using mouse models of conditioned reward and withdrawal. METHOD: Using male ICR mice, the ability of repeated ceftriaxone injections to modulate the development and reinstatement of a nicotine-conditioned place preference (CPP) was evaluated. Additionally, nicotine withdrawal-associated signs were assessed. These included both physical (somatic signs and hyperalgesia) and affective (anxiety-related behaviors) withdrawal signs in mice. Finally, the effects of ceftriaxone on nicotine-induced antinociception and hypothermia after acute nicotine injection were measured. RESULT: Ceftriaxone had no effect on the development of nicotine preference but significantly attenuated nicotine-induced reinstatement of CPP. Furthermore, ceftriaxone reversed all nicotine withdrawal signs measured in mice. CONCLUSION: Altogether, these findings show that a β-lactam antibiotic reduces nicotine withdrawal and nicotine-seeking behavior. Our results suggest that the documented efficacy of ceftriaxone against cocaine and morphine dependence-related behaviors effects extends to nicotine.
Authors: B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec Journal: Neuroscience Date: 2008-02-15 Impact factor: 3.590
Authors: Lori A Knackstedt; Steven LaRowe; Pascale Mardikian; Robert Malcolm; Himanshu Upadhyaya; Sarra Hedden; Athina Markou; Peter W Kalivas Journal: Biol Psychiatry Date: 2008-12-21 Impact factor: 13.382
Authors: Aric C Madayag; Sierra J Stringfield; Kathryn J Reissner; Charlotte A Boettiger; Donita L Robinson Journal: Alcohol Clin Exp Res Date: 2017-03-13 Impact factor: 3.455
Authors: Fawaz Alasmari; Laura E Crotty Alexander; Jessica A Nelson; Isaac T Schiefer; Ellen Breen; Christopher A Drummond; Youssef Sari Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-03-27 Impact factor: 5.067
Authors: Joseph A Schroeder; Nicholas G Tolman; Faye F McKenna; Kelly L Watkins; Sara M Passeri; Alexander H Hsu; Brittany R Shinn; Scott M Rawls Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468